Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Nov;49(6):929-939.
doi: 10.1177/2168479015580384.

Partnering With Patients in the Development and Lifecycle of Medicines: A Call for Action

Affiliations
Free PMC article

Partnering With Patients in the Development and Lifecycle of Medicines: A Call for Action

Anton Hoos et al. Ther Innov Regul Sci. .
Free PMC article

Abstract

The purpose of medicines is to improve patients' lives. Stakeholders involved in the development and lifecycle management of medicines agree that more effective patient involvement is needed to ensure that patient needs and priorities are identified and met. Despite the increasing number and scope of patient involvement initiatives, there is no accepted master framework for systematic patient involvement in industry-led medicines research and development, regulatory review, or market access decisions. Patient engagement is very productive in some indications, but inconsistent and fragmentary on a broader level. This often results in inefficient drug development, increasing evidence requirements, lack of patient-centered outcomes that address unmet medical needs and facilitate adherence, and consequently, lack of required therapeutic options and high costs to society and involved parties. Improved patient involvement can drive the development of innovative medicines that deliver more relevant and impactful patient outcomes and make medicine development faster, more efficient, and more productive. It can lead to better prioritization of early research; improved resource allocation; improved trial protocol designs that better reflect patient needs; and, by addressing potential barriers to patient participation, enhanced recruitment and retention. It may also improve trial conduct and lead to more focused, economically viable clinical trials. At launch and beyond, systematic patient involvement can also improve the ongoing benefit-risk assessment, ensure that public funds prioritize medicines of value to patients, and further the development of the medicine. Progress toward a universal framework for patient involvement requires a joint, precompetitive, and international approach by all stakeholders, working in true partnership to consolidate outputs from existing initiatives, identify gaps, and develop a comprehensive framework. It is essential that all stakeholders participate to drive adoption and implementation of the framework and to ensure that patients and their needs are embedded at the heart of medicines development and lifecycle management.

Keywords: medicines development; patient involvement.

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article. The following authors are employees of GlaxoSmithKline (J.A., M.M.); UCB Biopharma (L.D.); MSD (Europe) Inc (A.J.); Merck & Co, Inc (J.R.); Pfizer Inc (R.F.S.); and Novartis Pharma AG (G.T.). The opinions expressed in this article are those of the authors and do not necessarily reflect the views of their employers or organizations.

Figures

Figure 1.
Figure 1.
Growth of EMA interactions with patients and consumer organizations between 2007 and 2013. Reproduced with permission from European Medicines Agency.
Figure 2.
Figure 2.
Patient engagement in the R&D process. Reproduced with permission from the National Health Council.
Figure 3.
Figure 3.
Patient engagement in regulatory decision making. Reproduced with permission from the National Health Council.
Figure 4.
Figure 4.
Patient roles in the clinical trials continuum. Adapted from Parkinson’s Disease Foundation materials and developed by the Clinical Trials Transformation Initiative. Reproduced with permission from the Parkinson’s Disease Foundation.

Similar articles

See all similar articles

Cited by 35 articles

See all "Cited by" articles

References

    1. Pharmaceutical Research and Manufacturers of America. Biopharmaceutical research industry profile. www.phrma.org/sites/default/files/pdf/PhRMA%20Profile%202013.pdf. Published July 2013. Accessed September 2014.
    1. European Federation of Pharmaceutical Industries and Associations. Pricing of medicines. www.efpia.eu/topics/industry-economy/pricing-of-medicines. Published 2014. Accessed December 2014.
    1. Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov. 2010;9:203–214. - PubMed
    1. Luce BR, Kramer JM, Goodman SN, et al. Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change. Ann Intern Med. 2009;151:206–209. - PubMed
    1. Djulbegovic B, Hozo I, Ioannidis JP. Improving the drug development process: more not less randomized trials. JAMA. 2014;311:355–356. - PubMed
Feedback